Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Cancer

• Main Authors: Tan Chongqing (Author), Li Sini (Author), Zeng Xiaohui (Author), Peng Liubao (Author), Peng Ye (Author), Qin Shuxia (Author), Wang Liting (Author), Wu Meiyu (Author), Wan Xiaomin (Author)
• Format: Book
• Published: Frontiers Media S.A., 2021-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Pembrolizumab is a guideline-recommended, both first- and second-line treatment option for microsatellite-instability-high (MSI-H)/mismatch repair-deficient (dMMR)advanced colorectal cancer patients. The aim of the present study is to investigates the health and economic outcomes of thre...